Intravenous Mistletoe Therapy: Integrative Oncology IA, IL, MO, GA, FL, TX San Antonio, Dallas, Houston

Introduction

Mistletoe extracts, derived from the European mistletoe plant (Viscum album L.), have been employed in complementary and alternative medicine for cancer treatment, particularly in anthroposophic approaches prevalent in Europe. While subcutaneous injections remain the most common route, intravenous (IV) administration has garnered attention for its potential to deliver higher doses and achieve systemic effects more rapidly. This blog post examines the scientific evidence surrounding IV mistletoe therapy in oncology, including its biological mechanisms, clinical outcomes, safety profile, and regulatory status, with a focus on implications for evidence-based practice.

Biological Mechanisms and Rationale

Mistletoe extracts contain bioactive compounds such as lectins, viscotoxins, and polysaccharides, which exhibit immunomodulatory, anti-proliferative, and pro-apoptotic properties in preclinical models. These components are postulated to enhance immune surveillance by stimulating natural killer cells, macrophages, and cytokine production, potentially counteracting tumor immune evasion. In the context of IV administration, higher bioavailability may amplify these effects compared to subcutaneous routes, though direct comparative studies are limited. Proponents suggest that IV mistletoe could mitigate chemotherapy-induced immunosuppression and improve patient resilience during conventional treatments.

Clinical Evidence from Trials and Reviews

Systematic reviews of controlled clinical trials indicate mixed but promising results for mistletoe therapy in cancer management. A review of 23 prospective studies reported significant benefits in 12, with positive trends in seven, particularly in terms of survival and quality of life (QoL). Specifically for IV administration, a Phase I trial at Johns Hopkins University involving 21 patients with advanced solid tumors demonstrated disease stabilization in five participants, lasting an average of 15 weeks, alongside improvements in QoL metrics. Another review highlighted reductions in chemotherapy-related adverse events and dose adjustments in non-small cell lung cancer patients treated with adjunctive mistletoe.

European sources provide substantial evidence, with anthroposophic mistletoe therapy widely studied in countries such as Germany, Switzerland, and Austria. A systematic review of prospective clinical trials on anthroposophic mistletoe extracts identified 16 randomized controlled trials (RCTs) and nine non-RCTs, demonstrating benefits in QoL and reduction of side effects from conventional therapies, with some evidence of survival prolongation in specific cohorts. For IV routes, a qualitative study incorporating a systematic review of IV mistletoe infusions analyzed four RCTs and retrospective studies, noting improvements in chemotherapy tolerability, immune parameters (e.g., prevention of granulocyte suppression), and survival in advanced colorectal cancer (e.g., median survival of 25 vs. 17 months when combined with 5-FU).

Additional European RCTs include a trial in advanced pancreatic cancer (n=220) using mistletoe extracts, which extended median overall survival (4.8 vs. 2.7 months; HR=0.49, p<0.0001), though primarily subcutaneous. A multicenter observational study in pancreatic cancer (n=240) reported longer survival with integrative mistletoe therapy (12.1 months with chemotherapy plus mistletoe vs. 7.3 months with chemotherapy alone). In breast cancer, an RCT (n=65) using Iscador showed reduced side effects like nausea and pain during chemotherapy. For colon/rectum cancer, a phase III RCT (n=22) with a single Iscador IV infusion post-surgery decreased natural killer cell suppression.

Case reports from Europe highlight IV applications: A patient with recurrent dedifferentiated liposarcoma achieved long-term survival (10.5 years) with IV and subcutaneous mistletoe. In metastatic renal cell carcinoma, sole high-dose IV mistletoe led to progression-free survival of 2.5 years. Complete remission was observed in metastatic melanoma after high-dose fever-inducing IV mistletoe, with tumor-free survival of 3.5 years.

However, evidence for definitive survival prolongation remains inconclusive. A randomized trial in melanoma patients found no extension in survival time with mistletoe extract. Observational data suggest benefits in symptom control and QoL for breast, gynecological, and pancreatic cancers, but high-quality randomized controlled trials are needed to confirm efficacy. Ongoing trials, such as those evaluating Helixor M for advanced tumors, continue to explore these outcomes.

Safety Profile and Side Effects

IV mistletoe therapy is generally well-tolerated, with adverse drug reactions (ADRs) being mild to moderate and dose-dependent. Common side effects include fatigue, nausea, chills, and localized inflammation, occurring in a minority of patients and resolving without intervention. Severe events, such as allergic reactions or fever, are rare but more likely at higher doses. Studies confirm lower ADR rates with IV compared to subcutaneous routes, and no increased risks in patients with autoimmune comorbidities. Nonetheless, monitoring is essential, and therapy should be administered under medical supervision.

Regulatory and Clinical Status in the United States

In the United States, mistletoe extracts are not approved by the Food and Drug Administration (FDA) for cancer treatment but are available through investigational channels, such as clinical trials or compassionate use programs. The National Cancer Institute acknowledges ongoing research, including Phase I studies at institutions like Johns Hopkins, which support further investigation. Integrative oncology clinics may offer IV mistletoe as adjunctive therapy, though patients should consult oncologists to ensure compatibility with standard regimens.

Conclusion

Intravenous mistletoe therapy presents a complementary option in cancer care, with evidence suggesting improvements in quality of life and symptom management, albeit with variable impacts on survival. While promising, the field requires more rigorous, large-scale trials to establish efficacy and optimal protocols. Healthcare professionals are encouraged to discuss this modality with patients seeking integrative approaches, emphasizing evidence-based integration and safety considerations. Future research may clarify its role in personalized oncology.

Yoon Hang Kim MD offers virtual integrative oncology program for patients in Iowa, Illinois, Missouri, Florida, Georgia and Texas including (Dallas, San Antonio, Austin and Houston)

References

Axtner, J., Steele, M., Kröz, M., Spahn, G., Matthes, H., & Schad, F. (2016). Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 16, Article 579. https://doi.org/10.1186/s12885-016-2594-5

Büssing, A., Bischof, M., Haisch, J., & Scheffold, A. (2005). Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Research, 25(6B), 4197–4202.

Büssing, A., Stumpf, C., Tröger, W., & Schietzel, M. (2008). Course of mitogen-stimulated lymphocytes in cancer patients under Viscum album therapy. Forschende Komplementärmedizin, 15(3), 124–130. https://doi.org/10.1159/000128976

Cazacu, M., Oniu, T., Lungoci, C., Mihalache, D., Cipak, A., Klinger, W., Weiss, T., & Zarkovic, N. (2003). The influence of isorel on the advanced colorectal cancer. Cancer Biotherapy & Radiopharmaceuticals, 18(1), 27–34. https://doi.org/10.1089/108497803321269313

Horneber, M. A., Bueschel, G., Huber, R., Linde, K., & Rostock, M. (2008). Mistletoe therapy in oncology. Cochrane Database of Systematic Reviews, 2008(2), Article CD003297. https://doi.org/10.1002/14651858.CD003297.pub2

Kienle, G. S., & Kiene, H. (2007). Complementary cancer therapy: A systematic review of prospective clinical trials on anthroposophic mistletoe extracts. European Journal of Medical Research, 12(3), 103–119.

Kienle, G. S., & Kiene, H. (2010). Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies. Integrative Cancer Therapies, 9(2), 142–157. https://doi.org/10.1177/1534735410369673

National Cancer Institute. (2024, November 6). Mistletoe extracts (PDQ®)–Health professional version. https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq

Oei, S. L., Thronicke, A., & Schad, F. (2019). Mistletoe and immunomodulation: Insights and implications for anticancer therapies. Evidence-Based Complementary and Alternative Medicine, 2019, Article 5893017. https://doi.org/10.1155/2019/5893017

Orange, M., Fonseca, M. P., Lace, A., von Laue, H. B., & Geider, S. (2010). Durable tumour responses following primary high dose induction with mistletoe extracts: Two case reports. European Journal of Integrative Medicine, 2(1), 41–47. https://doi.org/10.1016/j.eujim.2010.01.002

Orange, M., Lace, R., Fonseca, M. P., von Laue, B. H., Geider, S., & Kienle, G. S. (2012). Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: Two case reports. Global Advances in Health and Medicine, 1(1), 18–25. https://doi.org/10.7453/gahmj.2012.1.1.006

Paller, C. J., Wang, L., Fu, W., Mezghani, K., Naqibuddin, M., Mullins, C. D., & Antonarakis, E. S. (2023). Phase I trial of intravenous mistletoe extract in advanced cancer. Cancer Research Communications, 3(3), 338–346. https://doi.org/10.1158/2767-9764.CRC-23-0002

Reynel, M., Villegas, Y., Kiene, H., Werthmann, P. G., & Kienle, G. S. (2019). Bilateral asynchronous renal cell carcinoma with lung metastases: A case report of a patient treated solely with high-dose intravenous and subcutaneous Viscum album extract for a second renal lesion. Anticancer Research, 39(10), 5597–5604. https://doi.org/10.21873/anticanres.13754

Reynel, M., Villegas, Y., Werthmann, P. G., Kiene, H., & Kienle, G. S. (2021). Long-term survival of a patient with recurrent dedifferentiated high-grade liposarcoma of the retroperitoneum under adjuvant treatment with Viscum album L. extract: A case report. Integrative Cancer Therapies, 20, 153473542199008. https://doi.org/10.1177/1534735421990081

Schad, F., Axtner, J., Kröz, M., Matthes, H., & Steele, M. L. (2018). Safety of combined treatment with monoclonal antibodies and Viscum album L preparations and targeted therapies in oncological patients. Medicines, 5(1), Article 19. https://doi.org/10.3390/medicines5010019

Schad, F., Thronicke, A., Merkle, A., Matthes, H., & Steele, M. (2017). Immune-related adverse drug reactions in the eyes of integrative oncology: A cross-sectional study. BMC Complementary Medicine and Therapies, 17(1), Article 115. https://doi.org/10.1186/s12906-017-1636-5

Schink, M., Tröger, W., Dabidian, A., Goyert, A., Scheuerecker, H., Meyer, J., Fischer, I. U., & Glaser, F. (2007). Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. Forschende Komplementärmedizin, 14(1), 9–17. https://doi.org/10.1159/000098594

Thronicke, A., Steele, M. L., Grosse, C., Happe, A., & Schad, F. (2017). Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complementary and Alternative Medicine, 17(1), Article 534. https://doi.org/10.1186/s12906-017-2045-3

Tröger, W., Galun, D., Reif, M., Schumann, A., Stanković, N., & Milićević, M. (2013). Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival. European Journal of Cancer, 49(18), 3788–3797. https://doi.org/10.1016/j.ejca.2013.06.043

Tröger, W., Galun, D., Reif, M., Schumann, A., Stanković, N., & Milićević, M. (2014). Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: A randomized controlled trial. Deutsches Ärzteblatt International, 111(29-30), 493–502. https://doi.org/10.3238/arztebl.2014.0493

Werthmann, P. G., Hintze, A., & Kienle, G. S. (2017). Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract: A case report. Medicine, 96(46), e8731. https://doi.org/10.1097/MD.0000000000008731

Zänker, K. S., Matthes, H., Bock, P. R., & Hanisch, J. (2010). A specific mistletoe preparation (Iscador-Qu®) in colorectal cancer (CRC) patients: More than just supportive care? Journal of Cancer Science & Therapy, 2(3), 63–69. https://doi.org/10.4172/1948-5956.1000025